- Home
- CDE vs MDGL Comparison
CDE vs MDGL Comparison
Compare CDE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- MDGL
- Stock Information
- Founded
- CDE 1928
- MDGL 2011
- Country
- CDE United States
- MDGL United States
- Employees
- CDE N/A
- MDGL N/A
- Industry
- CDE Precious Metals
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- CDE Basic Materials
- MDGL Health Care
- Exchange
- CDE Nasdaq
- MDGL Nasdaq
- Market Cap
- CDE 5.7B
- MDGL 6.1B
- IPO Year
- CDE N/A
- MDGL N/A
- Fundamental
- Price
- CDE $14.67
- MDGL $432.89
- Analyst Decision
- CDE Strong Buy
- MDGL Strong Buy
- Analyst Count
- CDE 4
- MDGL 10
- Target Price
- CDE $9.69
- MDGL $463.78
- AVG Volume (30 Days)
- CDE 14.3M
- MDGL 402.0K
- Earning Date
- CDE 11-05-2025
- MDGL 10-30-2025
- Dividend Yield
- CDE N/A
- MDGL N/A
- EPS Growth
- CDE N/A
- MDGL N/A
- EPS
- CDE 0.39
- MDGL N/A
- Revenue
- CDE $1,459,632,000.00
- MDGL $515,547,000.00
- Revenue This Year
- CDE $81.88
- MDGL $394.12
- Revenue Next Year
- CDE $3.81
- MDGL $57.74
- P/E Ratio
- CDE $37.81
- MDGL N/A
- Revenue Growth
- CDE 63.68
- MDGL 3421.98
- 52 Week Low
- CDE $4.58
- MDGL $200.63
- 52 Week High
- CDE $14.75
- MDGL $443.00
- Technical
- Relative Strength Index (RSI)
- CDE 86.24
- MDGL 75.83
- Support Level
- CDE $11.41
- MDGL $422.02
- Resistance Level
- CDE $11.97
- MDGL $443.00
- Average True Range (ATR)
- CDE 0.48
- MDGL 16.41
- MACD
- CDE 0.19
- MDGL 0.56
- Stochastic Oscillator
- CDE 97.73
- MDGL 88.97
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.